Escitalopram: Nursing Drug Guide, Serotonin Syndrome & NCLEX Review

Escitalopram is available as generic tablets and oral solution and as the brand Lexapro. Always verify both generic name (escitalopram vs citalopram) and tablet strength—sound-alike SSRI names and strength errors are common on nursing units.

Single-entity products include escitalopram tablets (5 mg, 10 mg, 20 mg; 10 mg and 20 mg scored) and escitalopram oral solution (1 mg/mL; oral solution not currently marketed per labeling). Do not substitute racemic citalopram milligram-for-milligram—escitalopram is the active S-enantiomer with different exposure.

Escitalopram is an SSRI indicated for major depressive disorder (MDD) in adults and pediatric patients 12 years and older, and for generalized anxiety disorder (GAD) in adults and pediatric patients 7 years and older per prescribing information.

↔On a small screen, swipe or scroll sideways to see the full table.

The mechanism of escitalopram is presumed to involve potentiation of central serotonergic activity through inhibition of neuronal serotonin (5-HT) reuptake. It is the S-enantiomer of racemic citalopram. Nurses should focus on serotonergic toxicity risk when multiple serotonin-affecting drugs are present and on mood monitoring during early therapy.

Dosing is once daily with or without food. Increase at intervals of no less than one week. Maximum recommended dosage is 20 mg once daily for most adults; labeling notes no additional benefit was demonstrated at 20 mg over 10 mg in a fixed-dose MDD trial. Recommended dosage is 10 mg once daily in most elderly patients and in hepatic impairment.

Missed dose: If a dose is missed, take the next dose at the regular time—do not double doses. Follow prescriber or pharmacy guidance for outpatient missed doses; document inpatient omissions per protocol.

Pretreatment checks

• Confirm indication, allergies, and that patient is not taking MAOIs, linezolid, IV methylene blue, or pimozide; verify ≥14-day washout when switching antidepressants
• Verify escitalopram (not citalopram) and correct strength; review serotonergic and antiplatelet/anticoagulant medications
• Screen for suicidal ideation and personal/family history of bipolar disorder; obtain baseline sodium when risk factors present

Contraindications

• Concomitant MAOIs or use within 14 days of stopping an MAOI intended to treat psychiatric disorders (includes linezolid or IV methylene blue per labeling)
• Concomitant pimozide
• Known hypersensitivity to escitalopram, citalopram, or formulation excipients

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral tablet or oral solution once daily, with or without food.

• Give at the same time each day to support adherence; mean half-life about 27–32 hours supports once-daily dosing
• Use the prescribed strength (5 mg, 10 mg, 20 mg)—do not substitute citalopram or another SSRI without prescriber order
• When tapering or discontinuing, reduce gradually when possible—abrupt stop increases discontinuation syndrome risk

• Gradual improvement in depressive or anxiety symptoms over weeks—not immediate
• Early GI or sleep changes may appear before mood benefit—distinguish adverse effects from clinical worsening
• Reassess continued need periodically per prescriber—maintenance therapy may be required to prevent relapse

Escalate urgently when serotonergic, neuropsychiatric, or sodium-related toxicity is suspected.

• Serotonin syndrome: agitation, hallucinations, tachycardia, labile BP, hyperthermia, tremor, rigidity, diarrhea
• New or worsening suicidal thoughts or behaviors, especially in adolescents and young adults
• Seizure, coma, or altered mental status (including overdose)
• Severe hyponatremia signs: confusion, weakness, unsteadiness, seizures
• Signs of GI or other bleeding while on antiplatelet/anticoagulant therapy

↔On a small screen, swipe or scroll sideways to see the full table.

Frequency data above reflect LEXAPRO placebo-controlled MDD trial labeling unless noted as postmarketing.

LEXAPRO overdosage has been reported with delayed seizures and altered mental status including coma; cardiovascular toxicity including QRS and QTc prolongation, wide-complex tachyarrhythmias, and torsade de pointes (hypertension most commonly seen); and serotonin syndrome (higher risk with multiple proserotonergic drugs). Prolonged cardiac monitoring is recommended because arrhythmia risk may be delayed.

Antidote

Not specified in the reviewed prescribing information — management is supportive. Gastrointestinal decontamination with activated charcoal should be considered in patients who present early after overdose.

• Escitalopram vs citalopram — different isomer and exposure; not milligram-equivalent (e.g., 20 mg citalopram ≠ 20 mg escitalopram)
• Lexapro vs other “Lex-” brands — confirm antidepressant vs unrelated drug names on MAR and label
• 5 mg vs 10 mg vs 20 mg tablets — verify strength; maximum labeled dose is 20 mg once daily for most adults
• SSRI cross-dispense — sertraline, fluoxetine, paroxetine are not interchangeable milligram-for-milligram
• MAOI washout — 14-day gap when switching to or from MAOIs; document stop dates in MAR and reconciliation

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Mental status and suicidal ideation—especially first months and after dose changes
• Serotonin syndrome assessment when new antibiotics (e.g., linezolid), analgesics, or triptans are ordered
• Basic metabolic panel/sodium (hyponatremia), especially older adults; ECG when QT risk or overdose

Document

• Drug name verified as escitalopram, dose, route, time, and tablet strength administered
• Suicide risk screening, serotonin syndrome assessment, and patient response/teaching provided
• Interaction notifications, sodium results, and prescriber/pharmacy clarifications

• Take exactly as prescribed; do not stop abruptly—contact clinician before stopping
• Report agitation, fever, muscle rigidity, fast heartbeat, or dizziness immediately
• Report worsening depression, anxiety, suicidal thoughts, or unusual behavior changes—especially early in therapy
• Avoid starting MAOIs, St. John’s wort, or extra pain medicines without medical advice
• Full benefit may take several weeks; continue unless prescriber directs otherwise

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for escitalopram using a tabbed case (MAR, labs, history, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency sorting, clinical judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes around serotonergic stacking and suicidality surveillance.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.